However, this trend is not uniform; in a clinical trial report evaluating neoadjuvant ipilimumab in melanoma patients, the authors found that this treatment resulted in an increase in circulating Treg (both CD4+CD25hiFoxp3+ and CD4+CD25hiCD39+ T cells), and that increases in these Tregs correlated with enhanced progression-free survival (Tarhini et al., 2012). The gene discussed is CD4; the disease is melanoma.